Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report

Table 1 Mutations of the specimen

Gene	Type	Nucleotide	Protein	Frequency, %	Chromosome	Exon
ANGPT2	Missense	c.52G > A	p.Ala18Thr	29.6	8	1/9
CD276	Missense	c.91G > T	p.Val31Phe	59.4	15	3/10
CHD2	Missense	c.1972T > G	p.Ser658 Ala	59.2	15	16/39
CHEK1	Missense	c.497A > T	p.Lys166Met	32.4	11	6/13
DICER1	Missense	c.3923A > G	p.Asp1308Gly	37.3	14	21/27
DICER1	Missense	c.5439G > T	p.Glu1813Asp	32.4	14	25/27
DICER1	frameshift	c.2031dup	p.Ser678L eufsTer14	55.6	14	12/27
F8	missense	c.3347T > A	p.Phe1116Tyr	36.4	X	14/26
FAM46C	missense	c.476A >G	p.Asn159Ser	56.4	1	2/2
FAT4	missense	c.7269A > C	p.Leu2423Phe	70.3	4	8/17
FAT4	missense	c.12512G >A	p.Cys4171Tyr	21.5	4	14/17
FGFR4	missense	c.1463G > A	p.Gly488Asp	55.6	5	10/16
GID4	missense	c.785T > G	p.Phe262Cys	92.9	17	5/6
GNAS	missense	c.981G > T	p.Glu327Asp	22.3	20	12/13
HDAC9	missense	c.2704G > C	p.Ala902Pro	58.7	7	21/25
IGF2R	missense	c.2842A > T	p.Asn948	32.2	6	21/48
KLF5	missense	c.757A > C	p.Asn253His	41.3	13	2/4
MED12	missense	c.4809A > T	p.Gln1603His	36.5	X	35/45
MSH3	missense	c.2404G > T	p.Asp802Tyr	19.7	5	17/24
NF1	frameshift	c.3053_306 7delinsCAGT	p.Leu1018 SerfsTer7	89.3	17	23/58
NOTCH2	missense	c.5854G > C	p.Ala1952Pro	35.8	1	32/34
PALLD	missense	c.207T > G	p.Ser69Arg	70.5	4	2/21
PDK1	missense	c.374A > T	p.Lys125Met	97.2	2	3/12
POLE	missense	c.3218G > A	p.Gly1073Glu	56.4	12	26/49
PRKDC	missense	c.1413A > T	p.Lys471Asn	66.1	8	13/86
RARG	missense	c.744G > T	p.Leu248Phe	24.7	12	7/10
RICTOR	missense	c.3786A > T	p.Lys1262Asn	36.3	5	31/38
ROBO1	missense	c.3240G > T	p.Gln1080His	28.2	3	23/31
ROBO1	missense	c.3736G > T	p.Ala1246Ser	31.8	3	26/31
SETD2	missense	c.4407G > C	p.Met1469Ile	28.3	3	3/21
SLC34A2	missense	c.225G > C	p.Gln75His	22.8	4	3/13
SLIT2	missense	c.2425A > T	p.Ser809Cys	66.1	4	24/37
SMARCA2	missense	c.394G > A	p.Glu132Lys	22.9	9	4/34
STAT4	missense	c.1450A > T	p.Asn484Tyr	98.4	2	17/24
TMEM127	missense	c.380G > T	p.Arg127Leu	36.5	2	3/4
TP53	missense	c.751A > T	p.Ile251Phe	90.3	17	7/11
TRPS1	missense	c.2206A > G	p.Thr736Ala	31.4	8	5/7
UPF1	missense	c.1880A > T	p.Lys627Met	45.1	19	14/24

Table 2 Retrospective analyses of intracranial SFT treated with monotherapy

Ref.	Yr	Number of participants	CNS	Drug	RECIST		Choi		Median PFS in mo
					PR	SD	PR	SD	RECIST	Choi
Park et al[22]	2011	14	6	Temozolomide + bevacizumab	2	12	11	2	10.8	9.67
Stacchiotti et al[23]	2012	35	6	Sunitinib	2	17	14	5	6	7
Valentin et al[24]	2013	5	1	Sorafenib	NA	2	NA	NA	NA	NA
Maruzzo et al[25]	2015	13	NA	Pazopanib	1	8	5	4	4.7	NA
Ebata et al[26]	2018	9	2	Pazopanib	0	8	4	2	6.2	NA
Martin-Broto et al[27]	2019	36	5	Pazopanib	2	21	18	9	5.57	5.57

RECIST: Response Evaluation Criteria in Solid Tumors; Choi: Choi response criteria; PR: Partial response; SD: Stable disease; PFS: Progression-free survival; NA: Not available.